Skip to Main Content

An official website of the United States government

Principal Investigator
Rowena Yip
Icahn School of Medicine at Mount Sinai
Position Title
About this CDAS Project
NLST (Learn more about this study)
Project ID
Initial CDAS Request Approval
Apr 17, 2013
Mortality Reduction by year
We are interested in determining the rate of lung cancer deaths prevented by screening on an annual basis. The PLCO data is ideal for this due to its large size and long period of follow up. In this way we will see when the effect of screening becomes maximal as well as when the effect is no longer apparent. In order to make these determinations we will need to know when the screening occurred, and when the cancer was diagnosed, and also whether the cancer was diagnosed as a result of screening or was either interval or was diagnosed after screening was completed. We will also need to know whether the patient was alive or died of the cancer and any other information if available regarding competing cause of death or recurrent disease. We will also need to be able to compare this information with the control arm of the study.

1- Determine proportional reduction in mortality as a function of time
2- Determine when effects related to the screening reach their maximum
3- Determine when effects from screening are no longer apparent
4- Determine rates of competing caused of death


1) David Yankelevitz, Tisch Cancer Center, Mount Sinai School of Medicine
2) Claudia Henschke, Tisch Cancer Center, Mount Sinai School of Medicine
3) Paolo Boffetta, Institute for Translational Epidemiology, Mount Sinai School of Medicine

Related Publications